OTTAWA, June 2 /PRNewswire-FirstCall/ - Hard to Treat
Diseases (HTDS; http://www.htdsmedical.com/) Collagenna Skin Care
Products participated at the Esthetique Spa International Trade
Show this past May 30 & 31 in
Toronto, Ontario.
www.spa-show.com
Collagenna Skin care Products Inc. presented its line of
products to Esthetic and Spa Professionals over the past 2 days in
Toronto Canada. This show is a
professional trade show open only to industry professional and the
initial attendance figures are estimated at around 7500 visitors.
Collagenna Skin Care Products used the opportunity to present its
new products such as the DermaResolve (TM) Peptide Serum as well as
the Cellulite reducing Alphaderm Cream.
Collagenna's Ontario District Sales Manager, Jerry Stepkoff states "This show was very well
attended and we are pleasantly surprised by the enquiries we
received regarding our line. For the second year in a row we were
fortunate enough to have some of our existing clients come and help
us in our booth. It is always effective when a prospect can
actually meet somebody who is using the product line and is willing
to share their experiences. We sensed that the mood of the crowd
was more positive than in the past year and we expect to generate
some new sales as a result of this show."
In other news, Collagenna Skin Care Products has hired Mr.
Don Ginn of St Louis, Missouri as its new Regional Sales
Manager. Mr Ginn brings with him many years of experience in the
field of peptide sales and he has decided to join our staff and
help us develop distribution channels in the Mid-Western States.
His nomination will take place immediately.
The company reminds our shareholders and followers that the
company does not subscribe to the PinkSheets.Com Filing Service.
Its IR company web site section "CLIENT SUPPORT" TAB
www.minamargroup.net or this direct link
http://minamarmarketinggroup.helpserve.com/ should be reviewed by
its followers for further updates on this and other business
matters. Non-newsworthy events are not press released however
posted on this separate support sites to keep our followers advised
of day-to-day events, and the company corporate web site. For any
matters relating to retail investor queries or to send us the
company directly a message please click on the "INVESTOR SUPPORT"
TAB or this direct link www.minamargroup.net/helpdesk.
To be included in the company's email database for press
releases, industry updates, and non-weekly activity at the company
that may or may not be news released, please subscribe or opt in
mailer at www.minamargroup.com/updates.
Safe Harbor Statement
Information in this filing may contain statements about future
expectations, plans, prospects or performance of Hard to Treat
Diseases, Inc. that constitute forward-looking statements for
purposes of the safe harbor Provision's under the Private
Securities Litigation Reform Act of 1995. The words or phrases "can
be," "expects," "may affect," "believed," "estimate," "project,"
and similar words and phrases are intended to identify such
forward-looking statements. HTDS Corporation cautions you that any
forward-looking information provided by or on behalf of Hard to
Treat Diseases, Inc. is not a guarantee of future performance. None
of the information in this filing constitutes or is intended as an
offer to sell securities or investment advice of any kind. Hard to
Treat Diseases, Inc.'s actual results may differ materially from
those anticipated in such forward-looking statements as a result of
various important factors, some of which are beyond Hard to Treat
Diseases, Inc.'s control. In addition to those discussed in Hard to
Treat Diseases, Inc.'s press releases, public filings, and
statements by Hard to Treat Diseases, Inc.'s management, including,
but not limited to, Hard to Treat Diseases, Inc.'s estimate of the
sufficiency of its existing capital resources, Hard to Treat
Diseases, Inc.'s ability to raise additional capital to fund future
operations, HTDS Corporation's ability to repay its existing
indebtedness, the uncertainties involved in estimating market
opportunities and, in identifying contracts which match Hard to
Treat Diseases, Inc.'s capability to be awarded contracts. All such
forward-looking statements are current only as of the date on which
such statements were made. Hard to Treat Diseases, Inc. does not
undertake any obligation to publicly update any forward-looking
statement to reflect events or circumstances after the date on
which any such statement is made or to reflect the occurrence of
unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only,
please contact medicalinfo@htdsmedical.com; For any corporate
matters, please contact www.minamargroup.com/helpdesk
SOURCE Hard to Treat Diseases